# Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Canonical URL: https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-septem-7fdba8e6
Ticker: RLAY
Company: Relay Therapeutics
Source: Relay Therapeutics
Published: 2026-09-01 20:46 EST
## Summary

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company...

## Article Body
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:

2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 9:15 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo ® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn .

Contact: Mitch Maisel mmaisel@relaytx.com

Media: Katie Engleman 1AB 919-333-7722 katie@1abmedia.com
## Recent Company News
- 2026-09-01 20:46 EST — [Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-septem-7fdba8e6) — Source: Relay Therapeutics
- 2026-08-06 20:05 EST — [Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates](https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-u-f325a004) — Source: Relay Therapeutics
- 2026-07-30 20:05 EST — [Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2026-financial-results-and-corpora-957fff80) — Source: Relay Therapeutics
- 2026-05-27 20:05 EST — [Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03) — Source: Relay Therapeutics
- 2026-05-21 00:21 EST — [Relay Therapeutics Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-00372d13) — Source: Relay Therapeutics
## Related News
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075)
- 2026-09-09 20:17 EST — COO — [CooperCompanies Announces Third Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2026-results-0256684b)
- 2026-09-09 20:15 EST — COO — [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization](https://biopharmsignal.com/news/COO/coopercompanies-completes-strategic-review-increases-share-repurchase-authorizat-c3b7ff3b)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment](https://biopharmsignal.com/news/NBTX/nanobiotix-participera-la-conf-rence-h-c-wainwright-28th-annual-global-investmen-8b1208fb)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-co-bd8b771d)